Open an account

Vyome Holdings

HIND · NASDAQ

$1.84+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.84

About HIND

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 9 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

Employees
9
Headquarters
San Clemente, California
Listed
Oct 6, 2016
Sector
Health Care
Industry
Pharmaceuticals
Website
reshapelifesciences.com

HIND key statistics

Market cap
12.91M
Price-earnings ratio
1.04
Dividend yield
—
Average volume
13.16K
Volume
8.25K
Open price
$1.86
High today
$1.88
Low today
$1.83
52 Week high
$6.56
52 Week low
$1.75

Vyome Holdings (HIND) at a glance

Vyome Holdings (HIND) last traded at $1.84, with a market cap of 12.91M and a price-to-earnings ratio of 1.04.

Today the stock has traded between $1.83 and $1.88. The current price is 0.5% above the day's low and 2.1% below its high.

Volume so far is 8.25K shares, below the average of 13.16K shares a day.

Over the past year Vyome Holdings has ranged from $1.75 to $6.56, and now sits 2% of the way up that range.

Vyome Holdings met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.10 per share against an estimate of -$0.1938.

The average analyst price target is $9.01, 389.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $9.01
Low
$3.54
Now
$1.84
High
$15.75

HIND earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 41.3% on average.

  1. Q1 FY23: reported -$9,048.00 per share against an estimate of -$24,906.36
  2. Q2 FY23: reported -$6,264.00 per share against an estimate of -$10,589.64
  3. Q3 FY23: reported -$4,640.00 per share against an estimate of -$7,099.20
  4. Q4 FY23: reported -$639.62 per share against an estimate of -$1,064.88
  5. Q1 FY24: reported -$522.00 per share against an estimate of -$946.56
  6. Q4 FY25: reported -$0.2082 per share against an estimate of -$0.3468
  7. Q1 FY26: reported -$0.15 per share against an estimate of -$0.1836
  8. Q2 FY26: reported -$0.10 per share against an estimate of -$0.1938

HIND news

  • Press releaseBusiness Wire

    Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

  • Press releaseBusiness Wire

    Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

  • Press releaseBusiness Wire

    Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releaseBusiness Wire

    Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

  • Press releaseBusiness Wire

    Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

  • Press releaseBusiness Wire

    Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

  • Press releaseBusiness Wire

    Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Similar companies

Companies in the same industry as Vyome Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.